botulinum toxin type a

This medicine is authorised for use in the European Union.


Nuceiva is a medicine used to temporarily improve the appearance of vertical frown lines between the eyebrows. It is used in adults less than 65 years of age who have moderate to severe facial lines and in whom those lines are having a significant psychological impact.

Nuceiva contains the active substance botulinum toxin type A.

This EPAR was last updated on 10/06/2022

Authorisation details

Product details
Agency product number
Active substance
Botulinum toxin type A
International non-proprietary name (INN) or common name
botulinum toxin type a
Therapeutic area (MeSH)
Skin Aging
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Evolus Pharma B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Apollolaan 151
1077 AR Amsterdam,

Product information

07/06/2022 Nuceiva - EMEA/H/C/004587 - IAIN/0028

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other muscle relaxants, peripherally acting agents

Therapeutic indication

Temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.

Assessment history

How useful was this page?

Add your rating
3 ratings